Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106186 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SLC6A4TDP1CYP1A2CYP2D6 | |
| SCHEMBL17911630 | 0.89 | ESR1 (0.39) | ALDH1A1TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9310814 | 0.84 | SLC6A4 (0.41) | ALDH1A1SLC6A4TDP1CYP1A2CYP2D6 | |
| SCHEMBL6164452 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SLC6A4TDP1CYP1A2CYP2D6 | |
| SCHEMBL7413858 | 0.79 | PPARG (0.40) | SLC6A4CYP1A2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL1109844 | 0.78 | SLC6A4 (0.39) | ALDH1A1SLC6A4NPSR1PPARGPPARA | |
| SCHEMBL7405563 | 0.77 | SLC6A4 (0.46) | ALDH1A1SLC6A4PPARGPPARANFE2L2 | |
| SCHEMBL13265662 | 0.77 | ALDH1A1 (0.44) | ALDH1A1SLC6A4TDP1CYP1A2CYP2D6 | |
| SCHEMBL3053959 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SLC6A4NPSR1PPARGPPARA | |
| SCHEMBL8890078 | 0.75 | ALDH1A1 (0.40) | ALDH1A1SLC6A4TDP1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | claimed |
| EP-2570128-B1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | ALDH1A1 3599/4885SLC6A4 25/4885TDP1 353/4885 |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | ALDH1A1 40/4885SLC6A4 4072/4885TDP1 3655/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | ALDH1A1 3941/4885SLC6A4 114/4885TDP1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.